肿瘤细胞治疗研究
英文原题：Novel cellular immunotherapies for hematological malignancies: recent updates from the 2021 ASH annual meeting.
细胞免疫治疗，包括CAR-T（CAR-T）细胞治疗和CAR-自然杀伤（CAR-NK）细胞治疗，近年来经历了广泛的临床研究和发展。
细胞免疫治疗，包括CAR-T（CAR-T）细胞治疗和CAR-自然杀伤（CAR-NK）细胞治疗，近年来经历了广泛的临床研究和发展。CAR-T细胞治疗现已成为一种强大的癌症治疗方法，具有巨大潜力，在血液系统恶性肿瘤的治疗中展现出显著的抗肿瘤活性。在2021年ASH年会上，关于急性淋巴细胞白血病（ALL）、淋巴瘤、急性髓系白血病（AML）和多发性骨髓瘤（MM）的报告取得了众多突破。通用型CAR-T细胞和CAR-NK细胞治疗，以及诱导多能干细胞（iPSC）衍生的免疫治疗，提供了巨大的“现货型”优势。本综述总结了2021年ASH年会上报告的血液系统恶性肿瘤细胞免疫治疗的主要进展和更新。
Cellular immunotherapy, including the chimeric antigen receptor T (CAR-T) cell therapy and CAR- natural killer (CAR-NK) cell therapy, has undergone extensive clinical investigation and development in recent years. CAR-T cell therapy is now emerging as a powerful cancer therapy with enormous potential, demonstrating impressive anti-tumor activity in the treatment of hematological malignancies. At the 2021 ASH annual meeting, numerous breakthroughs were reported concerning acute lymphocytic leukemia (ALL), lymphoma, acute myeloid leukemia (AML), and multiple myeloma (MM). Universal CAR-T cell and CAR-NK cell therapy, as well as induced pluripotent stem cell (iPSC)-derived immunotherapy, offer great "off-the-shelf" benefits. Major development and updates of cellular immunotherapy for hematological malignancies reported at the 2021 ASH annual meeting are summarized in this review.
MEMBER ACCOUNT
登录成功会直接打开下一页。
